non-nucleoside reverse transcriptase inhibitor


Also found in: Thesaurus, Medical, Acronyms, Wikipedia.
Related to non-nucleoside reverse transcriptase inhibitor: NRTI, nucleotide reverse transcriptase inhibitors

non-nucleoside reverse transcriptase inhibitor

n. Abbr. NNRTI
Any of a various antiviral drugs, such as delavirdine, that interfere with the activity of the enzyme reverse transcriptase, are not structurally similar to natural nucleosides, and are used chiefly to treat HIV infection.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.non-nucleoside reverse transcriptase inhibitor - an antiviral drug used against HIV; binds directly to reverse transcriptase and prevents RNA conversion to DNA; often used in combination with other drugs
delavirdine, Rescriptor - a non-nucleoside reverse transcriptase inhibitor (trade name Rescriptor) used to treat AIDS and HIV
drug cocktail, HAART, highly active antiretroviral therapy - a combination of protease inhibitors taken with reverse transcriptase inhibitors; used in treating AIDS and HIV
nevirapine, Viramune - a non-nucleoside reverse transcriptase inhibitor (trade name Viramune) used to treat AIDS and HIV
reverse transcriptase inhibitor - an antiviral drug that inhibits the action of reverse transcriptase in retroviruses such as HIV
References in periodicals archive ?
These are called reverse transcriptase inhibitors, and there are two subclasses within this group--nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI).
Agouron acquired the rights to develop and commercialize a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Shionogi & Co.
These guidelines include information about the use of abacavir ([Ziagen.sup.TM]) and the use of efavirenz ([Sustiva.sup.TM]), a non-nucleoside reverse transcriptase inhibitor, for treating HIV infection in children.
- The US Food and Drug Administration has approved two new HIV-1 medicines: Delstrigo, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and Pifeltro (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines, US-based pharmaceutical company Merck (NYSE: MRK) said.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor and is presently being marketed as Edurant, while dolutegravir is an integrase inhibitor marketed as Tivicay.
has entered into a license and collaboration agreement with Tibotec Pharmaceuticals for the development and commercialization of a once-daily, fixed-dose antiretroviral regimen containing Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg) for treatment-naive HIV-infected individuals.
This is the first anti-HIV drug in the class called non-nucleoside reverse transcriptase inhibitor (NNRTI).
In December, Bristol-Myers Squibb and Gilead Sciences announced that they will work together to develop a fixed-dose combination of Sustiva, a non-nucleoside reverse transcriptase inhibitor ("non-nuke"), and Truvada, a combination pill containing the nucleoside reverse transcriptase inhibitor ("nuke") Emtriva and the nucleotide reverse transcriptase inhibitor Viread.
Other factors associated with severe hepatotoxicity in this study were use of nevirapine-containing drugs, which were associated in those taking a non-nucleoside reverse transcriptase inhibitor with both early (OR 4.00) and late (OR 3.38) severe hepatotoxicity.
Another new anti-HIV drug in the non-nucleoside reverse transcriptase inhibitor (NNRTI) class that has shown promise ("Full Pipeline: Success of experimental AIDS drugs offers promise of future therapies," SN: 2/22/03, p.
Sustiva (efavirenz; formerly called DMP-266) is a new non-nucleoside reverse transcriptase inhibitor from DuPont Merck.
Odefsey is indicated in the European Union for the treatment of adults and adolescents (ages 12 years and older with body weight at least 35 kg) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load less than 100,000 HIV-1 RNA copies/ml.

Full browser ?